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Budget impact analysis of robotic
exoskeleton use for locomotor training
following spinal cord injury in four SCI
Model Systems
Daniel Pinto1,2* , Mauricio Garnier3, Jason Barbas4,5, Shuo-Hsiu Chang6, Susan Charlifue7,8, Edelle Field-Fote9,10,
Catherine Furbish9, Candy Tefertiller11, Chaithanya K. Mummidisetty12,13, Heather Taylor14,15,
Arun Jayaraman13,16 and Allen W. Heinemann17

Abstract
Background: We know little about the budget impact of integrating robotic exoskeleton over-ground training into
therapy services for locomotor training. The purpose of this study was to estimate the budget impact of adding
robotic exoskeleton over-ground training to existing locomotor training strategies in the rehabilitation of people
with spinal cord injury.
Methods: A Budget Impact Analysis (BIA) was conducted using data provided by four Spinal Cord Injury (SCI) Model
Systems rehabilitation hospitals. Hospitals provided estimates of therapy utilization and costs about people with spinal
cord injury who participated in locomotor training in the calendar year 2017. Interventions were standard of care
walking training including body-weight supported treadmill training, overground training, stationary robotic systems
(i.e., treadmill-based robotic gait orthoses), and overground robotic exoskeleton training. The main outcome measures
included device costs, training costs for personnel to use the device, human capital costs of locomotor training, device
demand, and the number of training sessions per person with SCI.
Results: Robotic exoskeletons for over-ground training decreased hospital costs associated with delivering locomotor
training in the base case analysis. This analysis assumed no difference in intervention effectiveness across locomotor
training strategies. Providing robotic exoskeleton overground training for 10% of locomotor training sessions over the
course of the year (range 226–397 sessions) results in decreased annual locomotor training costs (i.e., net savings)
between $1114 to $4784 per annum. The base case shows small savings that are sensitive to parameters of the BIA
model which were tested in one-way sensitivity analyses, scenarios analyses, and probability sensitivity analyses. The base
case scenario was more sensitive to clinical utilization parameters (e.g., how often devices sit idle and the substitution of
high cost training) than device-specific parameters (e.g., robotic exoskeleton device cost or device life). Probabilistic
sensitivity analysis simultaneously considered human capital cost, device cost, and locomotor device substitution. With
probabilistic sensitivity analysis, the introduction of a robotic exoskeleton only remained cost saving for one facility.
Conclusions: Providing robotic exoskeleton for over-ground training was associated with lower costs for the locomotor
training of people with SCI in the base case analyses. The analysis was sensitive to parameter assumptions.
Keywords: Economic, Budget impact analysis, Spinal cord injury, Robotics, Locomotor training
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Background
Between 249,000 to 363,000 persons live with disabilities
due to spinal cord injuries (SCI) in the United States, and
approximately 17,730 individuals experience new SCI each
year [1]. The average age of SCI onset is 43 years, affording
the opportunity to resume active community involvement
and employment. Despite strong incentives to resume
activities, much depends on the restoration of upper and
lower limb function. The inability to stand and walk not
only limits community involvement and employment but
these functional limitations also impose significant secondary health conditions. These conditions include depression,
pressure ulcers, severe spasticity, pain, limited joint range of
motion, contractures, muscle atrophy, bone loss, and
impaired digestive, respiratory, renal, and cardiovascular
function [2]. Each condition markedly reduces health and
quality of life of persons with SCI. In addition to the physical burden, spinal cord injury accounts for significant
health care costs ranging from $368,562 to $1,129,302 in
first year costs and $44,766 to $196,107 in annual health
care costs depending on the severity of injury [1].
For most individuals, some form of functional limitation
persists; however, improvement in mobility and function
is possible following the injury. The preservation of volitional motor or sensory function below the lesion level
provides an opportunity for motor recovery from intensive
training during rehabilitation. This population has great
potential for motor recovery and walking. Locomotor
training is a standard of care for the rehabilitation of the
individual with incomplete SCI. Likewise, walking is usually one of the primary goals of rehabilitation due to
physiological and social benefits [3, 4].
Conventional locomotor training strategies include those
in which body-weight is supported while clinicians may
manually facilitate stepping motions. This training requires
multiple personnel to assist with support or lower extremity
movement. Although body-weight supported treadmill training (BWSTT) and overground training (OGT) remain common locomotor training strategies, alternative strategies
using robotic therapy (RT) devices require less human capital
and allow greater repetition than typically is delivered in
personnel-intensive approaches [5]. RT may enhance therapists’ productivity and effectiveness while facilitating neurological recovery [5]. RT devices have several advantages,
including a structure that provides stability, programmable
force-production that facilitates lower extremity movement,
[6, 7] precise measurement of forces, [5, 7, 8] and the ability
to perform repetitive, labor-intensive tasks [9, 10]. A limitation of many RT devices is their limited interaction with the
external environment. Many are stationary and only serve as
a tool for the promotion of neural recovery or exercise.
Robotic exoskeletons (RT-exo) are prescription devices
comprising an external, motorized orthosis that is placed
over paralyzed or weakened limbs for the purpose of
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facilitating standing, walking, climbing stairs, and performing activities of daily living [11, 12]. Exoskeletons
can be used at home, at work, and during rehabilitation
[13]. Thus, RT-exo may serve the therapeutic role proposed by stationary robotic devices [14] while allowing
mobility and more active community involvement.
Clinical efficacy

Multiple randomized trials have found outcomes associated
with RT to be no different from conventional therapy when
similar doses are compared [15–20];; however, a recent
meta-analysis of studies investigating RT in individuals with
SCI found greater improvement for walking independence
(3.73; 95% confidence interval [CI], − 4.92 to − 2.53;
P < .00001) and endurance (53.32 m; 95% CI, − 73.15 to −
33.48; P < .00001) in robot-assisted training groups [21].
Additional systematic reviews found improvement in locomotor recovery using robot-assisted therapy following SCI
[22]. Tefertiller and colleagues reported that RT is likely to
be at least as effective as therapy alternatives for locomotor
training for individuals with neurological injuries and diseases [14, 22]. Whereas RT-exo has less evidence supporting
its use versus treadmill-based RT, several pilot studies of RTexo have recently been published with preliminary evidence
of efficacy [10, 23]. Sale et al. used a prospective, quasiexperimental study, pre-post design and found that RT-exo
training resulted in significant improvements in timed upand-go (TUG), six minute walk test (6MWT), and ten meter
walk test (10MWT) [23]. Chang et al. randomized patients
to RT-exo versus conventional physical therapy and found
the RT-exo group to increase significantly in 6MWT, stride
length, and step length after the intervention [10].
RT-exo shares many of the features of treadmill-based
RT devices while allowing greater user autonomy and fewer
environmental restrictions than treadmill-based RT devices
[13]. A recent qualitative study of gym-based RT-exo users
identified themes supporting improved community integration [24]; however in a recent narrative overview of RT-exo,
the authors critiqued four RT-exo devices, suggesting that
they fall short of promises to reengage in activities set in
real-world contexts [25]. Furthermore, the authors suggest
that RT-exo is better suited for rehabilitation settings than
in home settings [25].
Cost considerations of new technology

New technology in health care is a substantial contributor to
rising costs, [26] creating tensions as different stakeholders
in the health care sector interpret the value added by the
new technology [27]. Health funders attempt to balance cost
control, access to treatment, and support for innovation.
Health technology producers seek financial reward for their
innovations and to fund further development. Patients and
clinicians perceive the new technology in terms of benefits
produced for the individual [26, 28]. In 1991, Neumann and
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Weinstein [29] identified ‘five facts’ of new medical technologies that remain true today:
1. On average new technologies improve health outcomes
2. Many new technologies do not improve health
outcomes and it is not always easy to discriminate
between effective and ineffective technologies.
3. On average new technologies add to health care costs
4. Diffusion of new technology often is inefficient
5. Demand for new technology almost always is high.
The rapid growth and development of robotic devices is
an excellent example of such a technology in rehabilitation.
The costs of robotic exoskeletons include a high initial purchase price (relative to competing rehabilitation technology),
annual maintenance costs, and training costs per physical
therapist user. Whereas many new technologies can be costinefficient, others have been shown to be cost-neutral or
cost-saving [26]. It has been suggested that there is potential
for new robotic technology in rehabilitation to be cost saving
if the cost of a robotic system could be offset by a decreased
need for rehabilitation personnel to conduct the laborintensive demands of rehabilitation [30]. Whereas robotic
exoskeletons initially have been considered a research tool
and a device for individual users intent on community use,
the robotic exoskeleton is less expensive than stationary robotic devices and may be an attractive option for rehabilitation hospitals as a device for training. An unfortunate reality
of technology is the delay between the rising clinical evidence
and the rate at which reimbursement changes to account for
the costs of technology [31].

Budget impact analysis – framework

We know little about the budget impact of integrating RTexo devices into routine therapy services. Carpino et al.
conducted a review and model-based cost-effectiveness
analysis of lower extremity robotics, showing RT-exo to be
cost-effective relative to conventional care and stationary
robotics; however, model assumptions have been criticized
[32]. Morrison performed an analysis of the financial feasibility of lower extremity robotics, but did not address
exoskeletal devices [33]. No budget impact analysis was
performed for RT-exo in these economic studies. A budget
impact analysis (BIA) provides a framework for synthesizing knowledge when healthcare systems wish to estimate
the financial consequences of purchasing new technology
[34]. A BIA is not designed to provide a single estimate applicable to all decision-makers, but instead reflects local
health systems’ environment and decision-makers’ varying
perspectives [34]. For the purpose of this study, we evaluate
a model that reflects the introduction or expansion of RTexo on the total health system budget at four model health
systems with different case mixes.
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Methods
BIA framework and conceptual model for SCI

Estimation of the budgetary impact of a new intervention
involves a comparison of the “world without” against the
“world with” an RT-exo locomotor strategy. The net difference in estimated health-care costs between these two scenarios constitutes the budgetary impact of the intervention.
The BIA framework takes into consideration health system
features, population eligibility, and resource use in order to
understand what current and future costs are for the treatment of a given condition (Fig. 1).
Figure 2 presents the conceptual model for the application
of BIA to SCI locomotor strategies, where individuals enter
into a rehabilitation facility following SCI and acute medical
management. Locomotor training strategies are part of what
constitutes rehabilitation following SCI for many patients.
Other rehabilitative services include physical medicine and
rehabilitation services, occupational therapy, social work,
vocational rehabilitation, and psychological services. For the
purposes of this analysis, we assume that all other services
remain unchanged with the substitution of RT-exo services
for other locomotor training strategies.
The perspective of the analysis is from the rehabilitation facilities, specifically Inpatient Rehabilitation Facilities and
Long Term Care Hospitals, as the purchasers of technology.
A retrospective pre-post study design was implemented to
estimate the treatment cost of locomotor strategies. The
budget impact of RT-exo was evaluated over one year. The
calculation was replicated in a Microsoft Excel-based spreadsheet. Probabilistic sensitivity analysis was conducted using R
Statistical Software [35].
Four SCI Model Systems agreed to collaborate on this
project: [1] The Shirley Ryan AbilityLab (formerly the
Rehabilitation Institute of Chicago), [2] Craig Hospital,
[3] Shepherd Center, and [4] TIRR Memorial Hermann.
Participating model system sites served as the primary
data source for estimates of resource utilization.
Model inputs

The base case scenario represents the most likely or preferred set of assumptions, and sensitivity analyses explore
deviations for this estimate [36]. Our base case model assumptions are presented in Tables 1-3 and Appendix 1.
Table 1 presents facility characteristics, estimated number
of individuals with SCI receiving locomotor training during the inclusion time period, and locomotor training
strategies considered in this exercise. We estimated cost
and utilization data from participating Model System sites,
details of unit costs and associated sources are included in
Appendix 1. The number of individuals with SCI who
were estimated to have received locomotor training was
multiplied by the average number of training sessions per
facility. The total number of training sessions per year was
then multiplied by the proportion of training sessions
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Fig. 1 Budget Impact Analysis Schematic

Fig. 2 Budget Impact Analysis Conceptual Model for Locomotor Training Market Share
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Table 1 Facility characteristics
Facility label

Hospital structure

Number of individuals with SCI/year
eligible for locomotor training

Number of sessions
offered per user

Number of locomotor training sessions
per year for individuals with SCI

A

LTCH

172

16

2752

B

IRF

248

16

3968

C

LTCH

94

24

2256

D

IRF

155

20

3105

Note: LTCH Long Term Acute Care Hospital, IRF Inpatient Rehabilitation Facility

devoted to available locomotor strategies, yielding the
number of locomotor sessions per strategy per year. Salary
data were populated from the Bureau of Labor Statistics
website (https://www.bls.gov/bls/blswage.htm) according
to the model system facility location.
Table 2 reports BIA inputs and key assumptions concerning the device costs, training costs, and human capital costs
associated with locomotor training in inpatient rehabilitation
facilities. Where facilities provided more specific data for the
analysis, we adapted the inputs accordingly. The duration of
all training sessions was assumed to be one hour, including
set-up time. We assumed all devices had an adoption rate of
50% across clinicians (i.e., the robotic device sits idle 50% of
the time). The adoption rate represents the rate at which
the new technology is accepted and the demand for the
locomotor training device. We are using assumptions for
training session time and adoption rate because RT-exo
currently is not used for treatment across facilities.
Table 3 reports the changes in locomotor training
strategies between the current and future market share
of locomotor strategies within the respective hospital
systems. The Appendix provides greater detail of BIA inputs with costs in 2017 USD.

training substituted), and exoskeleton device life (8 year device life – 3 year device life). A probabilistic sensitivity analysis was performed where uncertainty across all parameters
was considered simultaneously. For the probabilistic sensitivity analysis, we considered the uncertainty around human
capital cost. Finally, we also tested the assumption of varying
conventional locomotor training strategies by 10% (without
the inclusion of RT-exo) to assess the influence of varying
conventional locomotor strategies on budget impact as scenario analysis.

Sensitivity analysis

Sensitivity analysis

Several parameters are likely to influence the RT-exo BIA,
including device cost, the choice of locomotor strategy for
substitution, and the efficiency of the use of RT-exo. One
way sensitivity analyses will vary the following parameters:
cost of robotic exoskeleton (50, 200%), adoption rate of
robotic exoskeleton device (100–10%), training strategy
substituted (highest cost training substituted, lowest cost

The base case scenario was sensitive to several parameters,
such as the cost of a robotic exoskeleton, efficiency of robotic
exoskeleton use, training strategy substituted, and exoskeleton device life. Fig. 3 plots a series of one-way sensitivity
analyses showing the range of costs or savings associated
with a change in parameters across each facility. The greatest
savings were seen in Facility B ($14,704) where robotic

Results
In the base case scenario for all hospital systems, offering
RT-exo for locomotor training decreased hospital costs associated with delivering locomotor training (Tables 3 & 4).
Providing RT-Exo for 10% of locomotor training sessions
over the course of the year results in decreased annual costs
associated with locomotor training; these savings ranged
from $649 (Facility D) to $4784 (Facility B) per annum.
The base case scenario had RT-Exo replacing a combination of all currently used robotic services, treadmill training with body-weight support, and over-ground training. It
also assumed that RT-Exo was idle 50% of the time.

Table 2 Locomotor strategy cost components in base case analysis
BWSTT

Stationary robotic

OGT- low cost

OGT– high cost

RT-Exo

Device cost

$70,000

$350,000

$10,000

$225,000

$150,000

Maintenance contract

$8500/yr × 5 years

$15,000/yr maintenance × 5 years

N/A

$7500/yr × 5 years

$10,000/yr

Lifespan

5 years

5 years

10 years

20 years

5 years

Personnel*

1 physical therapist (PT),
1 Exercise specialist†, 2 aides

1 PT, 1 aide

1 PT, 1 aide

1 PT

1 PT, 1 aide

Training requirement†

1h

5h

1h

1h

18 h

*

Facility C specified using 1 PT and 3 exercise specialists
†
We assumed two personnel trained per site
BWSTT, body-weight supported treadmill training; OGT, overground training; RT-Exo, robotic exoskeleton
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Table 3 Current and projected proportion of locomotor training in base case analysis

Facility A, 2752
locomotor sessions/year

Current locomotor
training offerings

Current Market Share per locomotor strategy/
number of locomotor sessions*

Future Market Share per locomotor strategy
/number of locomotor sessions

BWSTT

33% / 908

31% / 881

Stationary robotic

16% / 440

11% / 303

Over-ground training

51% / 1404

48% / 1293

Robotic Exoskeleton
Facility B, 3968
locomotor sessions/year

10% / 275

BWSTT

61% / 2420

56% / 2063

Stationary robotic

5% / 198

3% / 119

Over-ground training

34% / 1349

31% / 1309

Robotic Exoskeleton
Facility C, 2256
locomotor sessions/year

10% / 397

BWSTT

34% / 767

30% / 677

Stationary robotic

33% / 744

30% / 677

Over-ground training

33% / 744

30% / 677

Robotic Exoskeleton
Facility D, 3105
locomotor sessions/year

10% / 226

BWSTT

39% / 1211

36%/1118

Stationary robotic

10% / 311

7%/217

Over-ground training

51% / 1584

47%/1459

Robotic Exoskeleton

10%/311

* Number of locomotor sessions per user and locomotor strategy market share is based on facility averages and utilization rates. BWSTT, body-weight supported
treadmill training

Table 4 Current and projected market share per locomotor strategy
Facility

Current locomotor
training offerings

Current Market Share: costs*
per locomotor strategy

Future Market Share: costs
per locomotor strategy

A: 2752 locomotor sessions/ year

BWSTT

$127,416

$119,700

Stationary robotic

$66,056

$45,582

Over-ground training

$104,171

$98,050

Robotic Exoskeleton

$0

$31,486

BWSTT

$363,747

$333,941

Stationary robotic

$31,105

$18,890

Over-ground training

$107,064

$97,627

Robotic Exoskeleton

$0

$46,674

Net difference = $294,818 (future costs) - $297,643 (current costs), Savings $2825
B: 3968 locomotor sessions/ year

Net difference = $497,133 (future costs) - $501,916 (current costs), Savings $4784
C: 2256 locomotor sessions/year

BWSTT

$124,178

$111,783

Stationary robotic

$115,357

$103,889

Over-ground training

$58,762

$52,903

Robotic Exoskeleton

$0

$27,179

BWSTT

$174,440

$161,030

Stationary robotic

$47,037

$33,089

Over-ground training

$119,009

$109,683

Robotic Exoskeleton

$0

$35,587

Net difference = $295,754 (future costs) - $298,297 (current costs), Savings $2543
D: 3105 locomotor sessions/year

Net difference = $338,993 (future costs) - $340,107 (current costs), Savings $1114
*Costs are in 2017 USD. BWSTT, body-weight supported treadmill training
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Fig. 3 Results from One-Way Sensitivity Analyses. The effect of parameter variation on the base case (depicted as point estimate). Costs are in 2017 USD

exoskeleton life was extended to 8 years, and the greatest cost
was seen in Facility B ($52,934) where robotic exoskeleton
adoption rate was limited to 10%. The probabilistic sensitivity
analysis simultaneously considered parameter uncertainty of
human capital costs (salary), device cost, and locomotor
training device substitution. The probabilistic sensitivity analysis produced a range of net budget impacts across facilities
from a net savings of $1247per annum in facility C to a net
cost of $1620 per annum in facility D. Full probabilistic sensitivity analysis results are presented in Appendix 2.
We explored additional scenario analyses where, instead
of choosing to introduce RT-exo, we shift market share to
each of the conventional locomotor training strategies by
10%, e.g., in Facility A we assess how locomotor training
costs change after we shift from 33 to 43% BWSTT. When
stationary robotic and BWSTT are each increased by 10%
locomotor training costs increase at all facilities. This is because of the higher personnel cost in BWSTT and higher
device cost of stationary robotics relative to the overground
training cost. When conventional over-ground training is
increased by 10% it lowers costs at all facilities. Full scenario
analyses are presented in Appendix 3. For all facilities,
the savings from increasing market share to conventional overground training are greater than the savings
from shifting market share to RT-exo.

Discussion
The base case analysis shows small savings that are sensitive
to cost or structural components of RT-exo. Despite the expense of RT-exo devices, savings related to a decrease in
staffing needs and training for the therapeutic device exist.
For hospital systems considering the addition of RT-exo as a
locomotor training strategy, those with a higher percentage
of human capital intensive strategies such as BWSTT may
experience reduced costs if the introduction of RT-exo substitutes for these locomotor training interventions. However,
the savings are very small with large degrees of uncertainty.
In the base case scenario, we assumed the robotic overground exoskeleton adoption rate would be 50%. This estimate may be too generous given two factors, the population
eligible for RT-exo and clinician acceptance of new technology. RT-exo is a new technology that clinicians could choose
not to use for locomotor training despite hospital purchasing decisions. Interestingly, the base case scenario was more
sensitive to assumptions on clinical utilization parameters
than device-specific parameters. For example, limiting the
RT-exo useful life to 3 years (versus 5) only resulted in an
increase in locomotor training cost per annum of between
$3847 and $7611 across facilities. However, if RT-exo was
adopted at a rate of 10%, i.e., the device is idle 90% of the
time (as opposed to the 50% used in our model), annual
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costs of locomotor training would increase between $32,096
and $52,934 across facilities. When considering all sensitivity
and scenario analyses the least costly alternative is when
over-ground training sessions are increased by 10%. This
makes intuitive sense because device costs and personnel
costs are lowest. Over-ground training is a well developed
and clinically integrated technology, therefore few efficiencies can be expected from changes in technological adoption
and further integration into clinical practice. Conversely,
further technological development stands to improve the
business case for RT-exo but barriers in adoption and integration can impair its efficiency. Issues of technological
adoption warrant additional attention.
Turchetti et al. provide a comprehensive overview of technology adoption with application to robotic devices in rehabilitation [31]. The authors discuss barriers organized
around technological, behavioral, organizational, and economic factors. Technological factors include ease of use,
level of training necessary for caregivers to master the technology, and the anthropomorphic design of the product
[31]. Of particular note with technological barriers is the
shift from roles once played by the clinician to the device
that may create behavioral barriers to adoption. Learning
new technologies requires effort on the part of clinicians, patient and caregivers, and resistance to change is a common
phenomenon. Organization factors may be manifested in
the need for redistribution of responsibilities and establishing a new organizational balance. Economic barriers include
the dearth of cost-effectiveness data and the discordance between the timing required for purchasing decisions and the
rate of change concerning reimbursement.
Another barrier to adoption is the different perspectives
on the value added by the new technology suggesting the
need for further economic studies that consider multiple
perspectives in order to address the interests of all stakeholders [31]. Swank and colleagues report on the feasibility
of integrating RT-exo as a part of inpatient rehabilitation for
an individual with SCI and illuminate on many aspects of
RT-exo adoption identified above [37]. Of note was the need
for additional training for intra- and inter-physical therapist
consistency with use of RT-exo despite being certified in use
of the device. Working with hospital administrators and
support staff was needed to address workflow issues such as
optimizing device sizing and adjust settings prior to the
rehabilitation visit.
We did not quantify several key considerations regarding
RT-exo in this analysis. Hospital systems may invest in RTexo as a means of building or maintaining their reputation
as a leader in the use of cutting-edge technology. In this
model, RT-exo is considered only as a substitute for locomotor training in the rehabilitation setting; however, there is
potential for RT-exo to augment some community mobility.
Devices such as RT-exo are likely to decrease in cost with
greater competition in the market [38]. Numerous robotic
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device companies are entering the market with several at
substantially lower price points than the price weight used
for this investigation, e.g., $30,000 instead of $150,000 [39].
One device manufacturer anticipates being able to produce
RT-exos at $10,000 – $15,000, [39] which would be comparable with the price weight used for our low cost OGT device. With the use of new medical devices, there is a deviceoperator interaction known as the ‘learning curve” effect
[40, 41] during which inefficiencies are more likely; this is
arguably the state that we are currently in with respect to
RT-exo use in rehabilitation and we anticipate an improved
business case in the future.
Study limitations

This project did not take into account differences in
locomotor training effectiveness between alternatives.
There is no strong evidence showing the superiority or
non-inferiority of RT-exo. The evidence for the comparative effectiveness of robotic overground exoskeleton
for locomotor training in SCI is limited, but several pilot
studies show promising results [10, 23], and multiple
clinical studies are underway or in development that will
add to the evidence base (ClinicalTrials.gov Identifier:
NCT03340792, NCT03477123, NCT02322125, NCT0344
3700). Therefore, the findings of this BIA must be interpreted with caution because we assume non-inferiority. In
addition, there is limited data on the risks to users with SCI
and personnel associated with locomotor training for RT-exo
relative to other locomotor training strategies [12]. The retrospective study design provides estimates for the number of
individuals with SCI who received locomotor training therapies in 2017. Individuals with high cervical incomplete injuries
who do not have upper extremity strength are not always eligible to use all RT-exo systems, but they are
eligible to receive locomotor training with one RT-exo
device and with other interventions. Therefore the
volume of eligible patients may be lower than our estimates suggest; however, devices under development
are designed to be used with individuals who have
higher levels of SCI [42]. We may have overestimated
eligibility across therapy types due to varying eligibility
criteria specific to each device (e.g., robotic exoskeleton device fit versus BWSTT fit criteria).

Conclusions
The assessment of economic efficiency-with robotic exoskeleton is in its infancy. Our model provides a framework upon which economic studies can build. Utilizing
RT-exo for locomotor training may be an efficient use of
hospital resources if key assumptions concerning efficacy
hold true and the technology is adopted within the
health system; however, a large degree of uncertainty
surrounds our estimates as evidence for differences in
the effectiveness of among approaches is limited.
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Appendix 1
Table 5 Unit costs and associated sources
Component

Cost/unit

Assumptions and sources

$150,000

5 year life-span+Annual maintenance contract
($10,000) × 5 years

Locomotor strategies
RT-exo
Litegait - overground training

$10,000

Rehabilitaton hospital purchasing department

Zero G track system

$225,000

Rehabilitaton hospital purchasing department
+Annual maintenance contract
($7500) × 5 years

Treadmill training with body-weight
support (BWS) - treadmill and
harness system

$70,000

Rehabilitaton hospital purchasing department
+Annual maintenance contract
($8500) × 5 years

Lokomat

$350,000

$350,000 + Annual maintenance contract
($15,000) × 5 years
Rehabilitaton hospital purchasing department

Personnel
PT

$53.95 – Facility A

2017 BLS mean hourly rate by state + 30%
benefits https://www.bls.gov/ooh/healthcare
/physical-therapists.htm

$56.68 – Facility B

$41.50*0.3 – Facility A

$58.08 – Facility C

$43.60 + 0.3 - Facility B

$51.58 – Facility D

$44.68 + 0.3 - Facility C
$39.69 + 0.3 – Facility D

PT Assistant

$33.66 – Facility A

2017 BLS mean hourly rate by state + 30%
benefits

$36.30 – Facility B

25.89 + 30% benefits – Facility A

$43.68 – Facility C

27.92 + 30% benefits – Facility B

$34.61 – Facility D

33.60 + 30% benefits – Facility C
26.62 + 30% benefits – Facility D

Exercise specialist

$31.94 – Facility A

Exercise physiologist

$34.46 – Facility B

2017 BLS mean hourly rate by state + 30%
benefits

$28.90 – Facility C

$24.57 - Facility A

$31.87 – Facility D

$26.51- Facility B
$22.23 - Facility C
$23.99 - Facility D

PT Aide/tech

$17.04 – Facility A

2017 BLS mean hourly rate by state + 30%
benefits

$19.44 – Facility B

$13.11+ 30% benefits – Facility A

$16.76 – Facility C

$14.95+ 30% benefits – Facility B

$20.15 – Facility D

$12.89+ 30% benefits – Facility C
$15.50 + 30% benefits – Facility D
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Appendix 2
Table 6 Full results of Probabilistic sensitivity analysis
Mean (SD)

95% CI

Current cost

318,727.09 (38,750.52)

244,101.81, 396,054.92

Future cost

319,901.66 (37,082.70)

248,223.86, 392,349.78

Difference

1174.56 (13,552.87)

−23,305.15, 30,106.35

Current cost

340,331.06 (39,527.96)

264,223.77, 418,017.98

Future cost

340,533.79 (37,800.31)

266,498.82, 414,476.83

Difference

202.73 (13,430.07)

−24,508.92, 28,976.15

Current cost

355,740.28 (39,565.62)

279,999.34, 432,895.62

Future cost

354,493.63 (37,927.97)

280,420.54, 428,026.15

Difference

− 1246.65 (13,663.67)

− 26,749.97, 27,183.83

Current cost

318,888.07 (39,101.88)

242,958.61, 395,990.05

Future cost

320,508.13 (37,354.01)

247,590.25, 393,909.77

Difference

1620.06 (13,422.23)

− 7404.26, 31,122.70

Facility A

Facility B

Facility C

Facility D

CI Credible Interval

Appendix 3
Table 7 Scenario Analysis where conventional training strategies (pre RT-exo) are fluctuated by 10%

Facility A,
2752
locomotor
sessions/year

Facility B,
3968
locomotor
sessions/year

Facility C,
2256
locomotor
sessions/year

Facility D,
3105
locomotor
sessions/year

Current
locomotor
training
offerings

Current Market Share per
Future Market Share per
locomotor strategy/number locomotor strategy
of locomotor sessions*
/number of locomotor
sessions
- 10% increase in body
weight support

Future Market Share per
locomotor strategy
/number of locomotor
sessions
- 10% increase in Stationary
robotic

Future Market Share per
locomotor strategy
/number of locomotor
sessions
- 10% increase in
Overground training

Body-weight
support

33% / 908

43% / 1183

28% / 771

28% / 771

Stationary
robotic

16% / 440

11% / 303

26% / 716

11% / 303

Over-ground
training

51% / 1404

46% / 1266

46% / 1266

61% / 1679

Body-weight
support

61% / 2420

71% / 2817

56% / 2222

55% / 2182

Stationary
robotic

5% / 198

1% / 40

15% / 595

1% / 40

Over-ground
training

34% / 1349

28% / 1111

29% / 1151

44% / 1746

Body-weight
support

34% / 767

43% / 970

29% / 654

29% / 654

Stationary
robotic

33% / 744

29% / 654

43% / 970

28% / 632

Over-ground
training

33% / 744

28% / 632

28% / 632

43% / 970

Body-weight
support

39% / 1211

49% / 1521

36% / 1118

34% / 1056

Stationary
robotic

10% / 311

5% / 155

17% / 528

5% / 155

Over-ground

51% / 1584

46% / 1428

47% / 1459

61% / 1894
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Table 7 Scenario Analysis where conventional training strategies (pre RT-exo) are fluctuated by 10% (Continued)
Current
locomotor
training
offerings

Current Market Share per
Future Market Share per
locomotor strategy/number locomotor strategy
of locomotor sessions*
/number of locomotor
sessions
- 10% increase in body
weight support

Future Market Share per
locomotor strategy
/number of locomotor
sessions
- 10% increase in Stationary
robotic

Future Market Share per
locomotor strategy
/number of locomotor
sessions
- 10% increase in
Overground training

Current Market Share:
costs* per locomotor
strategy

Future Market Share:
Stationary robotics

Future Market Share:
Overground training

training
Facility

Current
locomotor
training
offerings

A: 2752
locomotor
sessions/ year

BWS

$127,416

$165,994

$108,127

$108,125

Stationary
robotic

$66,056

$45,582

$107,004

$45,581

Over-ground
training

$104,171

$93,969

$93,969

$124,568

subtotal

B: 3968
locomotor
sessions/ year

C: 2256
locomotor
sessions/year

D: 3105
locomotor
sessions/year

Future Market Share:
Body weight support

$297,643

$305,545

$309,099

$278,274

Net difference

$7902

$11,456

$–19,359

BWS

$363,747

$423,360

$333,941

$327,980

Stationary
robotic

$31,105

$6674

$92,182

$6674

Over-ground
training

$107,064

$88,190

$91,336

$138,520

Subtotal

$501,916

$518,224

$517,459

$473,175

Net difference

$16,308

$15,542

$–28,742

BWS

$124,178

$160,172

$108,061

$108,061

Stationary
robotic

$115,357

$100,446

$148,656

$97,002

Over-ground
training

$58,762

$49,384

$49,384

$75,777

subtotal

$298,297

$310,001

$306,101

$280,840

Net difference

$11,705

$7804

$–17,457

BWS

$168,627

$211,837

$155,665

$147,023

Stationary
robotic

$47,037

$23,791

$79,581

$23,791

Over-ground
training

$119,009

$107,352

$109,683

$142,323

$334,673

$342,980

$334,929

$142,323

Net difference

$8307

$10,256

$–21,537

subtotal

* negative (−) values denote a net saving
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